|
private:brickellbiotech
|
8683674
|
Dec 3rd, 2020 12:00AM
|
Brickell Biotech, Inc.
|
600
|
20.00
|
Open
|
Pharmaceuticals
|
Dec 3rd, 2020 09:18AM
|
Dec 3rd, 2020 09:18AM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|
|
private:brickellbiotech
|
8683674
|
Dec 2nd, 2020 12:00AM
|
Brickell Biotech, Inc.
|
600
|
20.00
|
Open
|
Pharmaceuticals
|
Dec 2nd, 2020 11:37AM
|
Dec 2nd, 2020 11:37AM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|
|
private:brickellbiotech
|
8683674
|
Dec 1st, 2020 12:00AM
|
Brickell Biotech, Inc.
|
600
|
20.00
|
Open
|
Pharmaceuticals
|
Dec 1st, 2020 10:13AM
|
Dec 1st, 2020 10:13AM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|
|
private:brickellbiotech
|
8683674
|
Nov 30th, 2020 12:00AM
|
Brickell Biotech, Inc.
|
599
|
20.00
|
Open
|
Pharmaceuticals
|
Nov 30th, 2020 10:32AM
|
Nov 30th, 2020 10:32AM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|
|
private:brickellbiotech
|
8683674
|
Nov 29th, 2020 12:00AM
|
Brickell Biotech, Inc.
|
598
|
22.00
|
Open
|
Pharmaceuticals
|
Nov 29th, 2020 05:17PM
|
Nov 29th, 2020 05:17PM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|
|
private:brickellbiotech
|
8683674
|
Nov 28th, 2020 12:00AM
|
Brickell Biotech, Inc.
|
598
|
22.00
|
Open
|
Pharmaceuticals
|
Nov 28th, 2020 01:10PM
|
Nov 28th, 2020 01:10PM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|
|
private:brickellbiotech
|
8683674
|
Nov 27th, 2020 12:00AM
|
Brickell Biotech, Inc.
|
596
|
22.00
|
Open
|
Pharmaceuticals
|
Nov 27th, 2020 09:30AM
|
Nov 27th, 2020 09:30AM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|
|
private:brickellbiotech
|
8683674
|
Nov 26th, 2020 12:00AM
|
Brickell Biotech, Inc.
|
595
|
22.00
|
Open
|
Pharmaceuticals
|
Nov 26th, 2020 10:31AM
|
Nov 26th, 2020 10:31AM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|
|
private:brickellbiotech
|
8683674
|
Nov 25th, 2020 12:00AM
|
Brickell Biotech, Inc.
|
595
|
22.00
|
Open
|
Pharmaceuticals
|
Nov 25th, 2020 01:19PM
|
Nov 25th, 2020 01:19PM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|
|
private:brickellbiotech
|
8683674
|
Nov 24th, 2020 12:00AM
|
Brickell Biotech, Inc.
|
593
|
21.00
|
Open
|
Pharmaceuticals
|
Nov 24th, 2020 09:30AM
|
Nov 24th, 2020 09:30AM
|
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions.
Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.
Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace.
|
Open
|
|
Open
|
5777 Central Ave, Suite 102
|
Boulder
|
Colorado
|
US
|
80301
|
|
Brickell Biotech
|
|
Pharmaceuticals & Biotechnology
|